|Roman Skiepko, Ziemowit Ziętkowski, Urszula Skiepko, Wojciech Budny, Anna Bodzenta-Łukaszyk|
Introduction. So far, no clear criteria are available which could be used to assess effectiveness of asthma treatment. The lack of such criteria is related with divergences in the assessment of: pulmonary parameters, asthma control criteria, quality of life reported by patients, frequency of asthma exacerbations and the necessity of hospitalization, as well as biochemical and histological indicators of the inflammatory process. It is advisable to find and estimate indices which can help in long term evaluation of omalizumab treatment.
Aim. The aim of the study was the evaluation of clinical effectiveness of omalizumab in patients with uncontrolled allergic asthma with regard to selected indices in a 5-year follow-up.
Materials and methods. The study was performed in a group of 13 patients with chronic severe asthma according to GINA 2006 criteria, treated with omalizumab in 2007-2011. The assay of the effectiveness of the treatment was based on: ACT, FEV1, doses of ICS and OCS, use of rescue medication and frequency of exacerbations.
Results. Improvement of the selected indices was observed after 16 weeks of the treatment.
5-year follow-up showed further tendency for improvement of the studied parameters, including lower frequency of exacerbations, less frequent use of rescue medication procedure and reduced long-term intake of oral glycocorticosteroids.
Conclusions. Our results show that omalizumab is effective for improving clinical indices of asthma severity and spirometry tests in patients with severe chronic allergic asthma in whom asthma control could not be achieved by other medication.
keywords: astma, omalizumab, skuteczność kliniczna, asthma, omalizumab, clinical efficacy
pages: from 104 to 109
|estimated time of download (327 kB)|